Approximately half of patients with atrial fibrillation and with risk factors for stroke are not
treated with oral anticoagulation (OAC), whether it be with vitamin K antagonists (VKAs) or …

Background Real-world data on patients' and physicians' values related to the use of oral
anticoagulant (OAC) therapy for stroke prevention in patients with nonvalvular atrial …

Background Persistence to treatment affects clinical outcomes in patients with chronic
disease such as atrial fibrillation (AF). Methods This prospective cohort study included …

Background Direct oral anticoagulants are available for patients with atrial fibrillation.
Objective This study compared adherence and persistence of once-daily (QD) vs twice-daily …

Importance Patients with atrial fibrillation (AF) are at a proportionally higher risk of stroke
based on accumulation of well-defined risk factors. Objective To examine the extent to which …

Background Four direct oral anticoagulants (DOACs) have been brought to market for the
treatment of nonvalvular atrial fibrillation and venous thromboembolism. Many forces …

Objective Medication adherence is essential for effective stroke prevention in patients with
atrial fibrillation (AF). We aimed to assess whether adherence to direct oral anticoagulants …

Background In patients with atrial fibrillation, incomplete adherence to anticoagulants
increases risk of stroke. Non-warfarin oral anticoagulants (NOACs) are expensive; we …

Introduction Stroke prevention using oral anticoagulation (OAC) is the first management
priority in atrial fibrillation (AF). Despite the importance of good therapy adherence, real …

Introduction In the USA, there is a steady rise of atrial fibrillation due to the aging population
with increased morbidity. This study evaluated the risk of stroke/systemic embolism (S/SE) …